Loading page
Loading page
Loading substance route
DiPT is not habit-forming and the desire to use it can actually decrease with use. It is described as most often self-regulating.
No information exists regarding physical dependence or withdrawal symptoms. Unusually among psychedelics, DiPT did not show evidence of behavioral tolerance in rodent studies.
The exact toxic dose is unknown. DiPT is described as relatively free of autonomic side effects and toxicity indications, with no changes in vital signs observed at typical doses. A physician commenting on the compound noted 'the lack of significant toxic effects' as notable.
DiPT is known to chronically alter the perception of sound and speech in some users, which may persist beyond the acute effects; ear pressure ranging from mild to painful has been reported, particularly when combined with MDMA.
At typical doses, DiPT is described as producing lucid and clear-headed cognitive effects compared to other tryptamines. At very high doses (250mg), one report described delusional spiritual experiences including feeling spoken to by spirits and perceiving an 'anti-universe.' Confusion has been noted at higher doses.
DiPT produces convulsions at high doses in rodent studies. No human seizure cases are documented in the available literature.
DiPT was first characterized in the scientific literature by R.B. Barlow and colleagues in 1959. Alexander Shulgin began investigating the compound's effects in humans during the mid-1970s, with his initial findings dating to 1974 and basic properties disclosed in 1976. Shulgin published more…
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.
Listed as a Schedule I controlled substance under national drug control legislation.
Sweden's public health agency recommended classifying DiPT as a hazardous substance on May 15, 2019. Current legal status may have changed following this recommendation.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 due to the tryptamine catch-all clause, which covers structurally related compounds.
Controlled as a Designated Substance (Shitei-Yakubutsu) under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Classified as a Class C controlled substance due to its structural relationship to DMT, which is covered under analogue provisions in New Zealand drug law.
Not listed under Buchstabe A, B, C, or D of controlled substances legislation. May be considered legal to possess, though sale for human consumption could still raise regulatory issues.
Federally unscheduled, though it may be considered an analogue of DET or 5-MeO-DiPT under the Controlled Substances Act. Sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act. Specifically listed as Schedule I in Florida and Louisiana (since June 2013).
10 sources cited
